Hematopoyetic and lymphoid tumors

Anna Sureda Balari

PRINCIPAL INVESTIGATORS
  • Montserrat Arnan Sangerman
  • Concepción Boqué Genovard
  • Victòria Clapés Puig
  • Eva Domingo Domènech
  • Eva González Barca
  • Sonia González Rodríguez
  • Monica Mansilla Suarez
  • Santiago Mercadal Vilchez
  • Octavio Servitje Bedate
CLINICAL RESEARCHERS
  • Nadia Garcia Lozano
  • Sergio Cano Olivar
  • Ana Carla De Oliveira Ramos
  • Clara Maluquer Artigal
  • Alberto Mussetti
POSTDOCTORAL RESEARCHERS
  • Maria Cristina Marin Monerris
PREDOCTORAL RESEARCHERS
  • Maria Cecilia Vilas
SCIENTIFIC SUPPORT
  • Beatriz Patiño Gutierrez
  • Rocio Parody Porras
MANAGEMENT SUPPORT
  • Miriam Ratia Garcia
  • Meriem Kara
  • Miriam Espinosa Leiva
  • Damir Emanuel Blazevic Limone
Cancer
Oncobell

Scientific production

70

PAPERS

Average IF: 20,620

11

LED PAPERS

Average IF: 24,765

16 PUBLICATIONS IN FIRST DECILE

42 PUBLICATIONS IN FIRST QUARTILE

48 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Mussetti A, Sureda A. Second-line CAR T cells for lymphomas. Lancet. 2022;399(10343):2247-2249. doi:10.1016/S0140-6736(22)00790-5.
  • Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan E, Martinez Lopez J, Muller A, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan Dabaja M, Newsome S, Degtyarev E, Awasthi R, del Corral C, Andreola G, Masood A, Schuster SJ, Jager U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N. Engl. J. Med. 2022;386(7):629-639. doi:10.1056/NEJMoa2116596.
  • Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA 7 Investigators and Contributing Kite M. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N. Engl. J. Med. 2022;386(7):640-654. doi:10.1056/NEJMoa2116133.
  • de Latour RP, Kulasekararaj A, Iacobelli S, Terwel SR, Cook R, Griffin M, Halkes CJM, Recher C, Barraco F, Forcade E, Vallejo JC, Drexler B, Mear JB, Smith AE, Angelucci E, Raymakers R, de Groot MR, Daguindau E, Nur E, Barcellini W, Russell NH, Terriou L, Iori AP, La Rocca U, Sureda A, Sanchez Ortega I, Xicoy B, Jarque I, Cavenagh J, de Fontbrune FS, Marotta S, Munir T, Tjon JML, Tavitian S, Praire A, Clement L, Rabian F, Marano L, Hill A, Palmisani E, Muus P, Cacace F, Frieri C, Van Lint MT, Passweg JR, Marsh JCW, Socie G, Mufti GJ, Dufour C, Risitano AM, European Soc Blood Marrow T. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia. N. Engl. J. Med. 2022;386(1):11-23. doi:10.1056/NEJMoa2109965.
  • Pinato DJ, Aguilar Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom Davis T, Handford J, Sita Lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona García MC, Sharkey R, García Illescas D, Rizzo G, Perachino M, Saoudi Gonzalez N, Doonga K, Fox L, Roldán E, Gaidano G, Ruiz Camps I, Bruna R, Patriarca A, Martinez Vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini A, OnCovid study G. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncol. 2022;23(7):865-875. doi:10.1016/S1470-2045(22)00273-X.

Research highlights

PROJECTS

6 Ongoing competitive projects

27 Started clinical trials
34 Ongoing clinical trials

PUBLISHED WORKS

1 Clinical guideline

NETWORKS

AGAUR SGR GRC

Selected projects

  • 2022-112-1. AN OPEN-LABEL, MULTICENTER, PHASE IB/II TRIAL EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA. LABCORP DRUG DEVELOPMENT INC. Budget: 287320. 2022- . PI: González Barca, Eva.
  • FIS21065. Mejora de los resultados clínicos de los pacientes con mieloma múltiple extramedular. Posible aplicabilidad de modelos ortoxenografts en el estudio de las bases genéticas de la resistencia a fármaco. Instituto de Salud Carlos III (ISCIII). Budget: 264143. 2022-2024. PI: Sureda Balari, Anna.
  • 2022-138-1. A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia. IQVIA RDS Spain SL. Budget: 269030,3. 2022- . PI: Arnan Sangerman, Montserrat.
  • 2022-125-1. Ensayo clínico tipo basket (cesta) de fase 2, multicéntrico y abierto para evaluar la seguridad y eficacia de MK-2140 en monoterapia y en combinación en pacientes con neoplasias linfoides B agresivas e indolentes. MERCK SHARP & DOHME ESPAÑA S.A. Budget: 231246. 2022- . PI: González Barca, Eva.
  • 2022-185-1. ESTUDIO TI FASE 1B/2, ABIERTO, PARA EVALUAR LA SEGURIDAD Y TOLERANCIA DE EPCORITAMAB EN OMBINACIÓN CON AGENTES ANTINEOPLÁSICOS EN PACIENTES CON LINFOMA NO-HODGKIN. AbbVie Spain, S.L.U. Budget: 163200. 2022- . PI: Sureda Balari, Anna.